

I. Remarks:

Claims 1-15 are pending in the subject application and are subject to a species election.

II. Requirement for Species Election:

The Office has required elections of a single disclosed species selected from the following species for prosecution on the merits:

Claims 3-10 are drawn to eight patentably distinct combinations of transgene and lysosomal storage disease which is treated with the specific transgene; and

Claims 12-15 are drawn to four patentably distinct combinations of transgene and blood-clotting disease which is treated with the specific transgene.


Responsive to the requirement for an election of species, Applicants hereby elect the species wherein the blood-clotting disease is hemophilia B and the transgene is Factor VIII. Claims 1, 11, and 13 are readable thereon. This election is without traverse to the extent that it is understood that (a) the requirement will be withdrawn upon the finding of an allowable genus; and (b) any species withdrawn from consideration will be transferred to the elected subject matter unless it is found patentably distinct from the elected invention.

III. Conclusion:

No fee is deemed necessary in connection with the filing of this communication. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 07-1074.

1/30/06
Date

Respectfully submitted,



Jennifer D. Tousignant
Agent for Applicants
Registration No. 54,498
Telephone: (508) 270-2499
Facsimile: (508) 872-5415

GENZYME CORPORATION
15 Pleasant Street Connector
P.O. Box 9322
Framingham, Massachusetts 01701-9322